- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01542710
Bimatoprost/Timolol Versus Travoprost/Timolol
Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study
Study Overview
Detailed Description
PURPOSE: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.
METHODS: Patients with primary open angle glaucoma (POAG) were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measures were the mean change in IOP from baseline
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Kasr El Aini Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Glaucoma
Exclusion Criteria:
- No other ocular diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glaucoma fixed Combination Medications
|
Bimatoprost/Timolol fixed combination
Other Names:
Fixed combination of Travoprost and Timolol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of drop of intraocular pressures from baseline.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tamer A Macky, MD FRCS, Cairo University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Fixed Glaucoma Medications
- GFDU-2011
- GANDUO-2011 (Other Identifier: Cairo University)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama
-
Dr. Kaweh MansouriEnrolling by invitationGlaucoma, Angle-Closure | Surgery | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma; Drugs | Glaucoma, Pigmentary | Glaucoma Secondary | Glaucoma Open-Angle | Glaucoma Congenital | Glaucoma CapsulareSwitzerland
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
Clinical Trials on Ganfort
-
Allergan S.A. DE C.V..Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Ministry of Health, MalaysiaCompletedPrimary Open Angle Glaucoma | Ocular HypertensionMalaysia
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleGermany, Netherlands
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited Kingdom, Spain, Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Poland
-
AllerganCompletedOcular Hypertension | Glaucoma, Primary Open AngleGermany
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleChina
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleKorea, Republic of
-
Larissa University HospitalCompletedOcular Hypertension | GlaucomaGreece
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria